DK2384339T3 - Behandling af autoimmun sygdom ved modulering af annexin-1 (lipocortin 1) - Google Patents
Behandling af autoimmun sygdom ved modulering af annexin-1 (lipocortin 1) Download PDFInfo
- Publication number
- DK2384339T3 DK2384339T3 DK09774914T DK09774914T DK2384339T3 DK 2384339 T3 DK2384339 T3 DK 2384339T3 DK 09774914 T DK09774914 T DK 09774914T DK 09774914 T DK09774914 T DK 09774914T DK 2384339 T3 DK2384339 T3 DK 2384339T3
- Authority
- DK
- Denmark
- Prior art keywords
- anx
- cells
- antibody
- fragment
- annexin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
Claims (9)
1. Anti-Annexin-1 (Anx-Al)-antistof eller et fragment deraf der binder til Anx-Al til anvendelse i behandlingen afen autoimmun sygdom.
2. Anti-Anx-Al-antistoffet eller et fragment deraf ifølge krav 1, hvor anti-Anx-Al-antistoffet er et monoklonalt antistof eller et fragment deraf.
3. Anti-Anx-Al-antistoffet eller et fragment deraf ifølge krav 2, hvor det monoklonale antistof er humaniseret.
4. Anti-Anx-Al-antistoffet eller et fragment deraf ifølge et hvilket som helst af kravene 1 til 3, hvor fragmentet er et Fab-, F(ab')2- eller Fv-fragment eller et enkelt-kæde-Fv (scFv)-molekyle.
5. Anti-Anx-Al-antistoffet eller et fragment deraf ifølge et hvilket som helst af de foregående krav, hvor den autoimmune sygdom er valgt fra gruppen bestående af rheumatoid arthritis (RA), multipel sklerose (MS), systemisk lupus erythematosus (SLE), Addisons sygdom, Graves sygdom, scleroderma, polymyositis, diabetes mellitus, autoimmun uveoretinitis, ulcerativ colitis, pemphigus vulgaris, inflammatorisk tarmsygdom, autoimmun thyroiditis og psoriasis.
6. Anti-Anx-Al-antistoffet eller et fragment deraf ifølge krav 5, hvor den autoimmune sygdom er valgt fra gruppen bestående af rheumatoid arthritis (RA), multipel sklerose (MS) og systemisk lupus erythematosus (SLE).
7. Anvendelse af et anti-Anx-Al-antistof eller et fragment deraf der binder til Anx-Al til fremstillingen af et medikament til behandling af en autoimmun sygdom.
8. Anvendelse ifølge krav 7, hvor den autoimmune sygdom er valgt fra gruppen bestående af rheumatoid arthritis (RA), multipel sklerose (MS), systemisk lupus erythematosus (SLE), Addisons sygdom, Graves sygdom, scleroderma, polymyositis, diabetes mellitus, autoimmun uveoretinitis, ulcerativ colitis, pemphigus vulgaris, inflammatorisk tarmsygdom, autoimmun thyroiditis og psoriasis.
9. Anvendelse ifølge krav 8, hvor den autoimmun sygdom er valgt fra gruppen bestående af rheumatoid arthritis (RA), multipel sklerose (MS) og systemisk lupus erythematosus (SLE).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0822011.3A GB0822011D0 (en) | 2008-12-02 | 2008-12-02 | Treatment |
| PCT/GB2009/002810 WO2010064012A2 (en) | 2008-12-02 | 2009-12-02 | Treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2384339T3 true DK2384339T3 (da) | 2015-04-27 |
Family
ID=40262550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09774914T DK2384339T3 (da) | 2008-12-02 | 2009-12-02 | Behandling af autoimmun sygdom ved modulering af annexin-1 (lipocortin 1) |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8980255B2 (da) |
| EP (2) | EP2889312B1 (da) |
| JP (4) | JP2012510507A (da) |
| KR (1) | KR101792887B1 (da) |
| CN (2) | CN102272156A (da) |
| BR (1) | BRPI0917037A2 (da) |
| DK (1) | DK2384339T3 (da) |
| ES (1) | ES2535724T3 (da) |
| GB (1) | GB0822011D0 (da) |
| HK (1) | HK1159659A1 (da) |
| PL (1) | PL2384339T3 (da) |
| PT (1) | PT2384339E (da) |
| RU (1) | RU2554801C2 (da) |
| WO (1) | WO2010064012A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100986744B1 (ko) * | 2008-07-10 | 2010-10-08 | 주식회사 한랩 | 자동 평형형 원심분리기 및 그 제어 방법 |
| GB0822011D0 (en) | 2008-12-02 | 2009-01-07 | Queen Mary & Westfield College | Treatment |
| CN103097414B (zh) * | 2010-06-09 | 2016-05-18 | 伦敦大学玛丽皇后和威斯特-弗尔德学院 | 膜联蛋白1抗体 |
| US20130261066A1 (en) * | 2010-08-31 | 2013-10-03 | The Research Foundation Of State University Of New York | Treatment of inflammatory bowel diseases using a tripeptide |
| GB201121564D0 (en) | 2011-12-14 | 2012-01-25 | Queen Mary & Westfield College | Use of antibody |
| KR102065112B1 (ko) | 2013-02-28 | 2020-01-10 | 삼성전자주식회사 | 높은 항원 선택성을 갖는 항체의 스크리닝 방법 |
| CN104144091A (zh) * | 2013-05-10 | 2014-11-12 | 中国电信股份有限公司 | 家庭网关业务承载实现方法和家庭网关 |
| JP2016520650A (ja) * | 2013-06-05 | 2016-07-14 | アール−エヌエーヴィ・エルエルシー | スズ−１１７ｍでの免疫性、炎症性及び変形性関節炎の治療 |
| KR20150029457A (ko) | 2013-09-10 | 2015-03-18 | 삼성전자주식회사 | 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도 |
| GB201702091D0 (en) * | 2017-02-08 | 2017-03-22 | Medannex Ltd | Specific binding molecules |
| US20210353721A1 (en) * | 2018-08-07 | 2021-11-18 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1 |
| GB201813137D0 (en) | 2018-08-10 | 2018-09-26 | Medannex Ltd | Cancer treatment with an antibody |
| JP7224628B2 (ja) * | 2019-02-01 | 2023-02-20 | 国立研究開発法人産業技術総合研究所 | 抗ｍｃ１６抗体 |
| WO2023089150A1 (en) | 2021-11-18 | 2023-05-25 | Medannex Ltd. | Combination therapy for cancer |
| CN117018185A (zh) * | 2022-03-18 | 2023-11-10 | 江苏靶标生物医药研究所有限公司 | TNF-α纳米抗体与PGE2联用在制备溃疡性结肠炎药物中的应用 |
| CN116183933A (zh) * | 2023-02-21 | 2023-05-30 | 上海市第一人民医院 | 生物标志物组合物及其在制备评价机体免疫功能的产品中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
| US5565338A (en) * | 1990-06-04 | 1996-10-15 | La Jolla Institute For Allergy And Immunology | Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CN1169735A (zh) * | 1994-10-25 | 1998-01-07 | 葛兰素集团有限公司 | Cd23结合剂 |
| AU2002364607A1 (en) | 2001-12-28 | 2003-07-24 | The Burnham Institute | Novel ligand involved in the transmigration of leukocytes . |
| CN1726395A (zh) * | 2002-12-17 | 2006-01-25 | 北京诺赛基因组研究中心有限公司 | 胰腺癌的特异标记 |
| US8198020B2 (en) * | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| WO2005027965A1 (en) | 2003-09-24 | 2005-03-31 | Peter Krammer | Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis. |
| MY148646A (en) * | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| TWI445525B (zh) | 2004-06-02 | 2014-07-21 | Sidney Kimmel Cancer Ct | 用以偵測、成像和治療瘤新生或血管新生的血管標的物之用途 |
| KR20090029703A (ko) * | 2006-05-26 | 2009-03-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 이미다조아제피논 화합물 |
| GB0822011D0 (en) | 2008-12-02 | 2009-01-07 | Queen Mary & Westfield College | Treatment |
-
2008
- 2008-12-02 GB GBGB0822011.3A patent/GB0822011D0/en not_active Ceased
-
2009
- 2009-12-02 DK DK09774914T patent/DK2384339T3/da active
- 2009-12-02 PT PT97749147T patent/PT2384339E/pt unknown
- 2009-12-02 CN CN2009801533354A patent/CN102272156A/zh active Pending
- 2009-12-02 PL PL09774914T patent/PL2384339T3/pl unknown
- 2009-12-02 RU RU2011120411/15A patent/RU2554801C2/ru active
- 2009-12-02 ES ES09774914.7T patent/ES2535724T3/es active Active
- 2009-12-02 CN CN201710153383.XA patent/CN107096023A/zh active Pending
- 2009-12-02 EP EP15152742.1A patent/EP2889312B1/en active Active
- 2009-12-02 KR KR1020117013832A patent/KR101792887B1/ko active IP Right Grant
- 2009-12-02 US US13/131,927 patent/US8980255B2/en active Active
- 2009-12-02 WO PCT/GB2009/002810 patent/WO2010064012A2/en active Application Filing
- 2009-12-02 EP EP09774914.7A patent/EP2384339B1/en active Active
- 2009-12-02 JP JP2011539093A patent/JP2012510507A/ja active Pending
- 2009-12-02 BR BRPI0917037A patent/BRPI0917037A2/pt not_active Application Discontinuation
-
2012
- 2012-01-04 HK HK12100039.9A patent/HK1159659A1/xx unknown
-
2015
- 2015-02-06 US US14/616,320 patent/US20150239965A1/en not_active Abandoned
- 2015-02-13 JP JP2015026441A patent/JP2015134782A/ja active Pending
-
2016
- 2016-05-20 JP JP2016101196A patent/JP2016153426A/ja not_active Withdrawn
-
2019
- 2019-03-08 JP JP2019042101A patent/JP6813613B2/ja active Active
- 2019-09-03 US US16/558,602 patent/US20200157196A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0917037A2 (pt) | 2019-12-17 |
| WO2010064012A3 (en) | 2010-07-29 |
| JP2016153426A (ja) | 2016-08-25 |
| EP2384339B1 (en) | 2015-01-28 |
| US20200157196A1 (en) | 2020-05-21 |
| EP2384339A2 (en) | 2011-11-09 |
| EP2889312A2 (en) | 2015-07-01 |
| RU2011120411A (ru) | 2013-01-10 |
| CN102272156A (zh) | 2011-12-07 |
| JP2019104754A (ja) | 2019-06-27 |
| WO2010064012A2 (en) | 2010-06-10 |
| HK1159659A1 (en) | 2012-08-03 |
| KR101792887B1 (ko) | 2017-11-01 |
| US20150239965A1 (en) | 2015-08-27 |
| US8980255B2 (en) | 2015-03-17 |
| RU2554801C2 (ru) | 2015-06-27 |
| PL2384339T3 (pl) | 2015-06-30 |
| PT2384339E (pt) | 2015-05-22 |
| ES2535724T3 (es) | 2015-05-14 |
| KR20110099014A (ko) | 2011-09-05 |
| EP2889312A3 (en) | 2015-10-21 |
| JP2015134782A (ja) | 2015-07-27 |
| EP2889312B1 (en) | 2018-08-29 |
| JP6813613B2 (ja) | 2021-01-13 |
| CN107096023A (zh) | 2017-08-29 |
| JP2012510507A (ja) | 2012-05-10 |
| US20120034209A1 (en) | 2012-02-09 |
| GB0822011D0 (en) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2384339T3 (da) | Behandling af autoimmun sygdom ved modulering af annexin-1 (lipocortin 1) | |
| RU2744046C2 (ru) | ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА | |
| Coupel et al. | Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation | |
| McCarl et al. | ORAI1 deficiency and lack of store-operated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia | |
| US11926671B2 (en) | Antibodies and polypeptides directed against CD127 | |
| RU2596403C2 (ru) | Антитело к аннексину а1 | |
| JP2014512812A (ja) | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 | |
| EP2313432B1 (en) | Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders | |
| JP7487938B2 (ja) | 抗ｃｄ５ｌ抗体及びその使用 | |
| US8642041B2 (en) | Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation | |
| US10100107B2 (en) | Method for identifying a compound useful with myosin regulatory light chain polypeptide antibody for treatment of an inflammatory disease | |
| WO2024008960A1 (en) | Cnx antigen-binding molecules | |
| US20150329639A1 (en) | Compositions and methods for regulating erythropoiesis | |
| WO2021085295A1 (ja) | 免疫応答抑制剤 | |
| OA19665A (en) | Antibodies and polypeptides directed against CD127. | |
| EA041126B1 (ru) | Антитела и полипептиды, направленные против cd127 |